BASF (BAS GY) has reportedly approached Evonik (EVK GY) about a takeover, the FT reports citing sources; no guarantee that there will be an agreement

Newsquawk StaffPublished On the live feed at — 1 more headline followed before this page went public
Newsquawk headlinesUTC

Johnson & Johnson (JNJ) announced that TREMFYA met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in the Phase 4 STAR study

Daily US Conference Calendar - 25th September 2026: MCHP

BASF (BAS GY) has reportedly approached Evonik (EVK GY) about a takeover, the FT reports citing sources; no guarantee that there will be an agreement

Volkswagen (VOW3 GY) is, alongside Audi, recalling 2.86mln global vehicles, due to a bolt-breaking risk, KBA

Iranian Leader Adviser Mokhber says if Iran cannot have flights and receive airport services, then non one in the region can either, Nour News reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

Large-cap German chemicals combinations have been discussed repeatedly over the years, but completed mergers at this scale are rare; the sector has more often seen portfolio swaps, carve-outs and mid-sized bolt-ons than full corporate takeovers, partly because overlapping commodity chemical businesses attract prolonged antitrust scrutiny and German stakeholder structures (works councils, government interest in strategic industry) slow everything down. A source-based report with an explicit no-agreement caveat sits at the earliest stage of the M&A sequence: in past episodes of this kind the typical pattern is an initial pop in the target and a flat-to-softer reaction in the named acquirer, followed by drift until either a denial, a confirmed approach, or silence kills the story. The strategic logic here would be consolidation of domestic European chemicals capacity at a time of structurally high energy costs and Chinese overcapacity, pressures that have pushed peers toward restructuring rather than expansion. What separates signal from noise in such reports is the sourcing and the follow-through: confirmation or denial from either company, movement in the target's spread to peers, and any comment from regulators or labour representatives. Evonik's prior form includes being viewed as a steadier, more specialty-weighted business, which is the kind of asset that attracts strategic interest but also commands a control premium that has historically deterred deals of this size.

Related headlines

The whole workspace, free to try.

Try it free